Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

253 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CC chemokine receptor 5 and renal-transplant survival.
Fischereder M, Luckow B, Hocher B, Wüthrich RP, Rothenpieler U, Schneeberger H, Panzer U, Stahl RA, Hauser IA, Budde K, Neumayer H, Krämer BK, Land W, Schlöndorff D. Fischereder M, et al. Among authors: wuthrich rp. Lancet. 2001 Jun 2;357(9270):1758-61. doi: 10.1016/s0140-6736(00)04898-4. Lancet. 2001. PMID: 11403814
Histological findings to five years after early conversion of kidney transplant patients from cyclosporine to everolimus: an analysis from the randomized ZEUS study.
Eisenberger U, Budde K, Lehner F, Sommerer C, Reinke P, Witzke O, Wüthrich RP, Stahl R, Heller K, Suwelack B, Mühlfeld A, Hauser IA, Nadalin S, Porstner M, Arns W; ZEUS Study Investigators. Eisenberger U, et al. Among authors: wuthrich rp. BMC Nephrol. 2018 Jun 28;19(1):154. doi: 10.1186/s12882-018-0950-1. BMC Nephrol. 2018. PMID: 29954336 Free PMC article. Clinical Trial.
Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials.
Sommerer C, Witzke O, Lehner F, Arns W, Reinke P, Eisenberger U, Vogt B, Heller K, Jacobi J, Guba M, Stahl R, Hauser IA, Kliem V, Wüthrich RP, Mühlfeld A, Suwelack B, Duerr M, Paulus EM, Zeier M, Porstner M, Budde K; ZEUS and HERAKLES study investigators. Sommerer C, et al. Among authors: wuthrich rp. BMC Nephrol. 2018 Sep 19;19(1):237. doi: 10.1186/s12882-018-1031-1. BMC Nephrol. 2018. PMID: 30231851 Free PMC article.
Efficacy and safety of conversion from cyclosporine to everolimus in living-donor kidney transplant recipients: an analysis from the ZEUS study.
Lehner F, Budde K, Zeier M, Wüthrich RP, Reinke P, Eisenberger U, Mühlfeld A, Arns W, Stahl R, Heller K, Witzke O, Wolters HH, Suwelack B, Klehr HU, Stangl M, Hauser IA, Nadalin S, Porstner M, May C, Paulus EM, Sommerer C; ZEUS Study Investigators. Lehner F, et al. Among authors: wuthrich rp. Transpl Int. 2014 Nov;27(11):1192-204. doi: 10.1111/tri.12411. Epub 2014 Aug 20. Transpl Int. 2014. PMID: 25070687 Free article. Clinical Trial.
Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study.
Budde K, Lehner F, Sommerer C, Reinke P, Arns W, Eisenberger U, Wüthrich RP, Mühlfeld A, Heller K, Porstner M, Veit J, Paulus EM, Witzke O; ZEUS Study Investigators. Budde K, et al. Among authors: wuthrich rp. Am J Transplant. 2015 Jan;15(1):119-28. doi: 10.1111/ajt.12952. Epub 2014 Dec 17. Am J Transplant. 2015. PMID: 25521535 Free article. Clinical Trial.
Early conversion from cyclosporine to everolimus following living-donor kidney transplantation: outcomes at 5 years posttransplant in the randomized ZEUS trial.
Sommerer C, Budde K, Zeier M, Wüthrich RP, Reinke P, Eisenberger U, Mühlfeld A, Arns W, Stahl R, Heller K, Wolters HH, Suwelack B, Klehr HU, Hauser IA, Stangl M, Nadalin S, Dürr M, Porstner M, May C, Wimmer P, Witzke O, Lehner F. Sommerer C, et al. Among authors: wuthrich rp. Clin Nephrol. 2016 Apr;85(4):215-25. doi: 10.5414/CN108726. Clin Nephrol. 2016. PMID: 26932178 Clinical Trial.
Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study.
Budde K, Lehner F, Sommerer C, Arns W, Reinke P, Eisenberger U, Wüthrich RP, Scheidl S, May C, Paulus EM, Mühlfeld A, Wolters HH, Pressmar K, Stahl R, Witzke O; ZEUS Study Investigators. Budde K, et al. Among authors: wuthrich rp. Am J Transplant. 2012 Jun;12(6):1528-40. doi: 10.1111/j.1600-6143.2012.03994.x. Epub 2012 Mar 5. Am J Transplant. 2012. PMID: 22642473 Free article. Clinical Trial.
Bone disease after renal transplantation.
Kunzendorf U, Krämer BK, Arns W, Braun J, Grossmann J, Pietruck F, Schmidt-Gayk H, Schwarz A, Ziegler E, Sperschneider H, Wüthrich RP, Nonnast-Daniel B, Schindler R, Renders L. Kunzendorf U, et al. Among authors: wuthrich rp. Nephrol Dial Transplant. 2008 Feb;23(2):450-8. doi: 10.1093/ndt/gfm816. Epub 2007 Dec 1. Nephrol Dial Transplant. 2008. PMID: 18056071 Free article. Review. No abstract available.
Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry.
Spithoven EM, Kramer A, Meijer E, Orskov B, Wanner C, Abad JM, Aresté N, de la Torre RA, Caskey F, Couchoud C, Finne P, Heaf J, Hoitsma A, de Meester J, Pascual J, Postorino M, Ravani P, Zurriaga O, Jager KJ, Gansevoort RT; ERA-EDTA Registry; EuroCYST Consortium; WGIKD. Spithoven EM, et al. Nephrol Dial Transplant. 2014 Sep;29 Suppl 4(Suppl 4):iv15-25. doi: 10.1093/ndt/gfu017. Nephrol Dial Transplant. 2014. PMID: 25165182 Free PMC article.
The lymphotoxin β receptor is a potential therapeutic target in renal inflammation.
Seleznik G, Seeger H, Bauer J, Fu K, Czerkowicz J, Papandile A, Poreci U, Rabah D, Ranger A, Cohen CD, Lindenmeyer M, Chen J, Edenhofer I, Anders HJ, Lech M, Wüthrich RP, Ruddle NH, Moeller MJ, Kozakowski N, Regele H, Browning JL, Heikenwalder M, Segerer S. Seleznik G, et al. Among authors: wuthrich rp. Kidney Int. 2016 Jan;89(1):113-26. doi: 10.1038/ki.2015.280. Epub 2016 Jan 4. Kidney Int. 2016. PMID: 26398497 Free article.
253 results